Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
In subjects on boosted protease inhibitor (PI)-regimens who have elevated triglycerides, a
switch to fosamprenavir/ritonavir once daily followed by the addition of Lovaza will result
in 30% of patients achieving a reduction in fasting triglycerides < 200 mg /dL while
maintaining virologic suppression.